🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- H17182108
- Market Cap
- Mid Cap · $549 Million
- IPO
- 10/18/2016 · $14.00/share
Business: CRISPR Therapeutics AG is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA.
Company Contact
- CEO
- Rodger Novak, M.D.
- CFO
- Marc Becker
- Headquarters
- 200 Sidney St. Cambridge, MA 02139
- Phone
- 617-315-4600
- Investor Relations
- Chris Brinzey, Westwicke Partners · 339-970-2843 · chris.brinzey@westwicke.com